Status:
NOT_YET_RECRUITING
A Trial of Shengmai Liquid for Long COVID Fatigue.
Lead Sponsor:
Beijing University of Chinese Medicine
Collaborating Sponsors:
Institute of Chemistry - Vietnam Academy of Science and Technology
Beijing Ditan Hospital
Conditions:
Long COVID Fatigue
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
The goal of this clinical trial is to learn if Shengmai liquid works to treat Long Covid fatigue. It will also learn about the safety of Shengmai liquid. The main questions it aims to answer are: * D...
Eligibility Criteria
Inclusion
- Aged between 18 and 75 years;
- Meet the above diagnostic criteria;
- Meet the traditional Chinese medicine syndrome diagnostic criteria;
- Consent and sign the informed consent form
Exclusion
- Currently in need of or expected to require high-flow oxygen therapy, positive pressure ventilation, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) and other advanced respiratory support measures;
- Have a known history of active liver disease (excluding non-alcoholic fatty liver changes), including active hepatitis B or C infection, primary biliary cirrhosis, Child-Pugh class B or C liver function impairment, or acute liver failure. Liver function at screening shows any of the following: serum alanine aminotransferase (ALT) \>3× the upper limit of normal (ULN); serum aspartate aminotransferase (AST) \>3×ULN; serum bilirubin \>2×ULN;
- Undergoing dialysis treatment, or known to have moderate to severe renal impairment (i.e., an estimated glomerular filtration rate (eGFR) value calculated based on serum creatinine using the CKD-EPI formula ≤45 mL/min/1.73 m² within 6 months before screening);
- Moderate to severe congestive heart failure within 6 months before screening (according to the New York Heart Association classification criteria, with cardiac function class III or IV), experienced a stroke, myocardial infarction, or coronary artery stent implantation; or have uncontrolled hypertension (defined as systolic blood pressure exceeding 160 mmHg or diastolic blood pressure exceeding 100 mmHg, with relevant records). Significant or clinically relevant electrocardiogram abnormalities, such as second-degree type II atrioventricular block, left bundle branch block, etc.;
- Suffered from influenza A, influenza B, or other infectious diseases within 3 months before screening;
- Have/ever had severe neurological diseases (epilepsy, convulsions, or seizures) or mental illness, or have a family history of mental illness;
- Pregnant or breastfeeding. Women who are breastfeeding or have a positive pregnancy test before taking the medication;
- History of malignant tumors within 5 years before screening, with existing and progressing tumors, and patients who are expected to need treatment during the study period;
- Have chronic fatigue syndrome or autoimmune diseases (such as rheumatoid arthritis, systemic lupus erythematosus, etc.);
- Known allergy to any component of the study drug;
- Diseases judged by the investigator to be unsuitable for participation in this study;
- Taken traditional Chinese medicine containing Codonopsis pilosula, Ophiopogon japonicus, Schisandra chinensis, or Astragalus membranaceus within 2 weeks before screening;
- Participating in other drug or medical device-related studies at the same time
Key Trial Info
Start Date :
July 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 30 2026
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06980636
Start Date
July 1 2025
End Date
November 30 2026
Last Update
June 17 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.